A series of 2-pyrazoline derivatives (PS-1 to PS-16) were synthesized by reacting different aromatic/heteroaromatic aldehydes and ketones, in a two-step reaction through Claisen – Schmidt condensation, followed by cyclization of the resulting chalcones with hydrazine hydrate in the presence of a base using conventional and microwave approaches. The synthesized derivatives were characterized by various physicochemical methods including IR, 1H-NMR, 13C-NMR, and mass spectroscopic data and elemental analysis. The antidepressant and anti-anxiety activities were evaluated using suitable animal models. Compounds PS-3, and PS-14 showed noticeable antidepressant activity, by reducing the duration of immobility in both tests, while compounds PS-9 and PS-12 were found to possess good anxiolytic activity (by increasing the number of arm entries and open arm exploratory time) at the tested doses (50 and 100 mg/kg b.w.) in comparison to standard drugs imipramine and diazepam, respectively. In order to elucidate binding interactions of the synthesized derivatives to the MAO-A target protein, molecular docking was employed which demonstrated the key interactions with amino acid residues Phe208, Asn181, and Tyr407 at the binding site. Further, the ADME properties of the synthesized derivatives were predicted and found to fall within the stated limits.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
C. Binda, P. Newton-Vinson, F. Hubalek, et al., Nat. Struct. Biol., 9, 22 – 26 (2002).
M. Bortolato, K. Chen, and J. C. Shih, Adv. Drug Deliv. Rev., 60, 1527 – 1533 (2008).
R. Chawla, U. Sahoo, A. Arora, et al., Acta Pol. Pharm., 67, 55 – 61 (2010).
F. Chimenti, A. Bolasco, F. Manna, et al., J. Med. Chem., 47, 2071 – 2074 (2004).
F. Chimenti, A. Bolasco, F. Manna, et al., Curr. Med. Chem., 13, 1411 – 1428 (2006).
F. Chimenti, E. Maccioni, D. Secci, et al., J. Med. Chem., 48, 7113 – 7122 (2005).
P. Dixit, A. C. Tripathi, and S. K. Saraf, J. Heterocycl. Chem., 50, 1431 – 1436 (2013).
D. E. Edmondson, C. Binda, and A. Mattevi, Neurotoxicology, 25, 63 – 72 (2004).
N. Gokhan-Kelekci, S. Yabanoglu, E. Kupeli, et al., Bioorg. Med. Chem., 15, 5775 – 5786 (2007).
N. Gokhan, A. Yesilada, G. Ucar, et al., Arch. Pharm. (Weinheim), 336, 362 – 371 (2003).
V. Jayaprakash, B. N. Sinha, G. Ucar, et al., Bioorg. Med. Chem. Lett., 18, 6362 – 6368 (2008).
B. S. Jayashree, S. Arora, and K. N. Venugopala, Asian J. Chem., 20, 1 – 7 (2008).
M. Karuppasamy, M. Mahapatra, S. Yabanoglu, et al., Bioorg. Med. Chem., 18, 1875 – 1881 (2010).
S. Kumar, S. Bawa, S. Drabu, et al., Recent Pat. Antiinfect. Drug Discov., 4, 154 – 163 (2009).
P. Lidstrom, J. Tierney, B. Wathey, et al., Tetrahedron, 57, 9225 – 9283 (2001).
R. G. Lister, Psychopharmacology, 92, 180 – 185 (1987).
F. Manna, F. Chimenti, A. Bolasco, et al., J. Enzyme Inhib., 13, 207 – 216 (1998).
F. Manna, F. Chimenti, A. Bolasco, et al., Bioorg. Med. Chem. Lett., 12, 3629 – 3633 (2002).
N. Mishra and D. Sasmal, Bioorg. Med. Chem. Lett., 21, 1969 – 1973 (2011).
E. M. Nurminen, M. Pihlavisto, L. Lazar, et al., J. Med. Chem., 54, 2143 – 2154 (2011).
P. Pacher, E. Kohegyi, V. Kecskemeti, et al., Curr. Med. Chem., 8, 89 – 100 (2001).
S. S. Parmar, B. R. Pandey, C. Dwivedi, et al., J. Pharm. Sci., 63, 1152 – 1155 (1974).
S. Pellow, P. Chopin, S. E. File, et al., J. Neurosci. Meth., 14, 149 – 167 (1985).
A. Pletscher, Experientia, 47, 4 – 8 (1991).
R. D. Porsolt, Antidepressants, in S. J. Enna, J. B. Malick, E. Richelson (eds.), Neurochemical, Behavioral and Clinical Perspectives, Raven Press, New York (1981), pp. 129 – 139.
R. D. Porsolt, A. Bertin, M. Jalfre, Arch. Int. Pharmacodyn. Ther., 229, 327 – 336 (1977).
Y. Rajendra Prasad, A. Lakshmana Rao, L. Prasoona, et al., Bioorg. Med. Chem. Lett., 15, 5030 – 5034 (2005).
A. Sahoo, S. Yabanoglu, B. N. Sinha, et al., Bioorg. Med. Chem. Lett., 20, 132 – 136 (2010).
L. Steru, R. Chermat, B. Thierry, et al., Psychopharmacology, 85, 367 – 370 (1985).
K. L. Stirrett, J. A. Ferreras, V. Jayaprakash, et al., Bioorg. Med. Chem. Lett., 18, 2662 – 2668 (2008).
G. D. Tollefson, J. Clin. Psychiatry, 44, 280 – 288 (1983).
G. Ucar, C. Tas, and A. Tumer, Toxicon, 45, 43 – 52 (2005).
S. Valente, S. Tomassi, G. Tempera, et al., J. Med. Chem., 54, 8228 – 8232 (2011).
H. G. Vogel (ed.), Drug Discovery and Evaluation: Pharmacological Assays, Springer-Verlag, Berlin, Heidelberg (2002), pp 385 – 594.
P. Willner, P. J. Mitchell, Behav. Pharmacol., 13, 169 – 188 (2002).
M. B. Youdim, D. Edmondson, and K. F. Tipton, Nat. Rev. Neurosci., 7, 295 – 309 (2006).
S. Zisook, Psychosomatics, 26, 240 – 246, 251 (1985).
Acknowledgements
We express our sincere gratitude to Central Drugs Research Institute (CDRI), Lucknow, India for providing the library and sophisticated analytical instrument facilities. Authors are thankful to the All India Council for Technical Education (AICTE), New Delhi, India, for providing grant under the Research Promotion Scheme (RPS), through which the computational software facility has been made available at the host institute. We also want to acknowledge the technical support team/application scientists of Schrodinger Inc. for their help during computational studies.
Conflict of Interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Upadhyay, S., Tripathi, A.C., Paliwal, S. et al. Facile One-Pot Synthesis Methodology for Nitrogen-Containing Heterocyclic Derivatives of 3,5-Disubstituted 4,5-Dihydro-1H-Pyrazole, Their Biological Evaluation and Molecular Docking Studies. Pharm Chem J 51, 564–575 (2017). https://doi.org/10.1007/s11094-017-1655-7
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11094-017-1655-7